240 related articles for article (PubMed ID: 18376407)
1. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.
Ahuja SK; Kulkarni H; Catano G; Agan BK; Camargo JF; He W; O'Connell RJ; Marconi VC; Delmar J; Eron J; Clark RA; Frost S; Martin J; Ahuja SS; Deeks SG; Little S; Richman D; Hecht FM; Dolan MJ
Nat Med; 2008 Apr; 14(4):413-20. PubMed ID: 18376407
[TBL] [Abstract][Full Text] [Related]
2. Genetic factors that confer sensitivity to HAART in HIV-infected subjects: implication of a benefit of an earlier initiation of HAART.
Nakajima T; Kimura A
Pharmacogenomics; 2008 Sep; 9(9):1347-51. PubMed ID: 18781860
[TBL] [Abstract][Full Text] [Related]
3. CCL3L1-CCR5 genotype improves the assessment of AIDS Risk in HIV-1-infected individuals.
Kulkarni H; Agan BK; Marconi VC; O'Connell RJ; Camargo JF; He W; Delmar J; Phelps KR; Crawford G; Clark RA; Dolan MJ; Ahuja SK
PLoS One; 2008 Sep; 3(9):e3165. PubMed ID: 18776933
[TBL] [Abstract][Full Text] [Related]
4. Better CD4+ T cell recovery in Brazilian HIV-infected individuals under HAART due to cumulative carriage of SDF-1-3'A, CCR2-V64I, CCR5-D32 and CCR5-promoter 59029A/G polymorphisms.
Rigato PO; Hong MA; Casseb J; Ueda M; de Castro I; Benard G; Duarte AJ
Curr HIV Res; 2008 Sep; 6(5):466-73. PubMed ID: 18855658
[TBL] [Abstract][Full Text] [Related]
5. Association of CCR5-59029 A/G and CCL3L1 copy number polymorphism with HIV type 1 transmission/progression among HIV type 1-seropositive and repeatedly sexually exposed HIV type 1-seronegative North Indians.
Rathore A; Chatterjee A; Sivarama P; Yamamoto N; Singhal PK; Dhole TN
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1149-56. PubMed ID: 19886839
[TBL] [Abstract][Full Text] [Related]
6. Impact of highly active antiretroviral treatment on expression of HIV-1 coreceptors and ligand levels in peripheral blood from HIV-1 infected patients in China.
Fang J; Bai S; Wu L; Zhu X; Yao X; Jin C; Wang C
J Int Med Res; 2013 Oct; 41(5):1560-9. PubMed ID: 24043708
[TBL] [Abstract][Full Text] [Related]
7. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.
Laurichesse JJ; Persoz A; Theodorou I; Rouzioux C; Delfraissy JF; Meyer L
HIV Med; 2007 May; 8(4):213-9. PubMed ID: 17461848
[TBL] [Abstract][Full Text] [Related]
8. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.
Dolan MJ; Kulkarni H; Camargo JF; He W; Smith A; Anaya JM; Miura T; Hecht FM; Mamtani M; Pereyra F; Marconi V; Mangano A; Sen L; Bologna R; Clark RA; Anderson SA; Delmar J; O'Connell RJ; Lloyd A; Martin J; Ahuja SS; Agan BK; Walker BD; Deeks SG; Ahuja SK
Nat Immunol; 2007 Dec; 8(12):1324-36. PubMed ID: 17952079
[TBL] [Abstract][Full Text] [Related]
9. Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy.
Kulkarni H; Marconi VC; Agan BK; McArthur C; Crawford G; Clark RA; Dolan MJ; Ahuja SK
PLoS One; 2008; 3(11):e3671. PubMed ID: 18989363
[TBL] [Abstract][Full Text] [Related]
10. CCR5 genotype and pre-treatment CD4+ T-cell count influence immunological recovery of HIV-positive patients during antiretroviral therapy.
Carvalho-Silva WHV; Andrade-Santos JL; Guedes MCDS; Crovella S; Guimarães RL
Gene; 2020 May; 741():144568. PubMed ID: 32165289
[TBL] [Abstract][Full Text] [Related]
11. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.
Gonzalez E; Kulkarni H; Bolivar H; Mangano A; Sanchez R; Catano G; Nibbs RJ; Freedman BI; Quinones MP; Bamshad MJ; Murthy KK; Rovin BH; Bradley W; Clark RA; Anderson SA; O'connell RJ; Agan BK; Ahuja SS; Bologna R; Sen L; Dolan MJ; Ahuja SK
Science; 2005 Mar; 307(5714):1434-40. PubMed ID: 15637236
[TBL] [Abstract][Full Text] [Related]
12. CCL3L1 and HIV/AIDS susceptibility.
Bhattacharya T; Stanton J; Kim EY; Kunstman KJ; Phair JP; Jacobson LP; Wolinsky SM
Nat Med; 2009 Oct; 15(10):1112-5. PubMed ID: 19812561
[No Abstract] [Full Text] [Related]
13. Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia.
Nakajima T; Ohtani H; Naruse T; Shibata H; Mimaya JI; Terunuma H; Kimura A
Immunogenetics; 2007 Oct; 59(10):793-8. PubMed ID: 17874089
[TBL] [Abstract][Full Text] [Related]
14. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.
Yamashita TE; Phair JP; Muñoz A; Margolick JB; Detels R; O'Brien SJ; Mellors JW; Wolinsky SM; Jacobson LP
AIDS; 2001 Apr; 15(6):735-46. PubMed ID: 11371688
[TBL] [Abstract][Full Text] [Related]
15. CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus.
Mamtani M; Rovin B; Brey R; Camargo JF; Kulkarni H; Herrera M; Correa P; Holliday S; Anaya JM; Ahuja SK
Ann Rheum Dis; 2008 Aug; 67(8):1076-83. PubMed ID: 17971457
[TBL] [Abstract][Full Text] [Related]
16. Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis.
McKinney C; Merriman ME; Chapman PT; Gow PJ; Harrison AA; Highton J; Jones PB; McLean L; O'Donnell JL; Pokorny V; Spellerberg M; Stamp LK; Willis J; Steer S; Merriman TR
Ann Rheum Dis; 2008 Mar; 67(3):409-13. PubMed ID: 17604289
[TBL] [Abstract][Full Text] [Related]
17. CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans.
Aklillu E; Odenthal-Hesse L; Bowdrey J; Habtewold A; Ngaimisi E; Yimer G; Amogne W; Mugusi S; Minzi O; Makonnen E; Janabi M; Mugusi F; Aderaye G; Hardwick R; Fu B; Viskaduraki M; Yang F; Hollox EJ
BMC Infect Dis; 2013 Nov; 13():536. PubMed ID: 24219137
[TBL] [Abstract][Full Text] [Related]
18. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
19. Influence of variations in CCL3L1 and CCR5 on tuberculosis in a northwestern Colombian population.
Mamtani M; Mummidi S; Ramsuran V; Pham MH; Maldonado R; Begum K; Valera MS; Sanchez R; Castiblanco J; Kulkarni H; Ndung'u T; He W; Anaya JM; Ahuja SK
J Infect Dis; 2011 Jun; 203(11):1590-4. PubMed ID: 21592988
[TBL] [Abstract][Full Text] [Related]
20. Getting personal about treating HIV.
Neaton JD; Lane HC
Nat Med; 2008 Apr; 14(4):369-70. PubMed ID: 18391933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
